Cardiomyopathy and Embryo-Fetal Toxicity
- Pertuzuamab administration can result in subclinical and clinical cardiac failure. Evaluate left ventricular function in all patients prior to and during treatment with Pertuzuamab. Discontinue Pertuzuamab treatment for a confirmed clinically significant decrease in left ventricular function.
- Exposure to Pertuzuamab can result in embryo-fetal death and birth defects. Studies in animals have resulted in oligohydramnios, delayed renal development, and death. Advise patients of these risks and the need for effective contraception.
Patient Counseling Information
Updated January 2018